Balaxi Pharmaceuticals
Balaxi Pharmaceuticals Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Balaxi Pharmaceuticals Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Balaxi Pharmaceuticals Ltd trades at a P/E of 12.27× and P/B of 0.48×.
Valuation
Profitability
Growth
Financial Health
Balaxi Pharmaceuticals Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Balaxi Pharmaceuticals Ltd, switchable between annual and quarterly views, consolidated or standalone.
Balaxi Pharmaceuticals Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹126.65 Cr and reported EPS of ₹1.72.
| Period | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | 46 | 231 | 279 | 336 | 241 | 293 | 270 |
| Other Income | 3 | 2 | 5 | 3 | -3 | -4 | 3 |
| Total Income | 48 | 234 | 284 | 339 | 239 | 289 | 273 |
| Cost of Goods Sold (COGS) | 34 | 172 | 196 | 202 | 129 | 166 | 151 |
| Gross Profit | 12 | 59 | 84 | 134 | 113 | 127 | 119 |
| +Operating Expenses | 6 | 17 | 34 | 77 | 66 | 90 | 111 |
| EBITDA | 6 | 42 | 50 | 57 | 47 | 37 | 9 |
| +Non-Operating Expenses | 0 | 0 | 1 | 2 | -35 | 5 | 6 |
| Profit Before Tax (PBT) | 9 | 44 | 55 | 57 | 2 | 29 | 5 |
| +Tax Expense | 3 | 6 | 7 | 11 | 4 | 4 | 4 |
| Profit After Tax (PAT) | 6 | 38 | 48 | 46 | -2 | 25 | 1 |
| Earnings Per Share (EPS) | 1.22 | 7.45 | 9.53 | 9.03 | -0.44 | 4.54 | 0.26 |
| Diluted Shares Outstanding (Nos.) | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| +Additional Disclosures | 73 | 360 | 426 | 490 | 322 | 428 | 403 |
| Sales Growth % | — | 406.95 | 20.77 | 20.42 | -28.28 | 21.25 | -7.65 |
| YoY Sales Growth % | — | 406.95 | 20.77 | 20.42 | -28.28 | 21.25 | -7.65 |
| Material Cost % | 74 | 74 | 70 | 60 | 53 | 57 | 56 |
| Employee Cost % | 5 | 4 | 4 | 9 | 11 | 12 | 14 |
| Other Cost % | 9 | 4 | 8 | 14 | 16 | 19 | 27 |
| OPM % | 13 | 18 | 18 | 17 | 19 | 13 | 3 |
| Tax % | 31 | 14 | 13 | 19 | 218 | 13 | 73 |
| Profit Growth % | — | 524.79 | 24.96 | -3.56 | -105.19 | 1,150.28 | -94.35 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 6 | 42 | 50 | 55 | 45 | 35 | 6 |
Balaxi Pharmaceuticals segment analysis: revenue and profit mix.
Disclosed business segments at Balaxi Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
Balaxi Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Balaxi Pharmaceuticals Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Balaxi Pharmaceuticals Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Balaxi Pharmaceuticals Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Healthy financial structure with low debt-to-equity ratio of 0.23.
P/E ratio of 12.30 appears attractively valued versus industry peers.
Substantial 66% promoter stake demonstrates confidence in long-term vision.
Price-to-book value of 1.00 suggests fair valuation or appreciation potential.
Impressive 32.25% 5-year EBITDA CAGR reflects operational efficiency improvements.
What can break it.
Latest quarterly net profit declined -95.50% to 0.29 Cr, raising concerns.
ROCE at 13.00% is notably lower than major pharmaceutical peers.
FIIs significantly reduced stake from 18.57% to 3.50%, signaling decreased confidence.
Current stock price near 52-week low, 54% drop from high.
EPS growth significantly negative. -54.25% (3Y) and -77.55% (QoQ).
What would change my mind.
Trim if P/E re-rates above 16. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Balaxi Pharmaceuticals Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Balaxi Pharmaceuticals Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Balaxi Pharmaceuticals Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Balaxi Pharmaceuticals Ltd — derived from the live tape, not yesterday's close.
Balaxi Pharmaceuticals Ltd last traded at ₹26.67 with an intraday range of ₹26–₹27.3 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹26.67| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 29.91 | +3.24 | +12.16% |
| R3 | 28.61 | +1.94 | +7.29% |
| R2 | 27.96 | +1.29 | +4.82% |
| R1 | 27.31 | +0.64 | +2.41% |
| PIVOT | 26.66 | -0.01 | -0.05% |
| CURRENT | 26.67 | — | — |
| S1 | 23.41 | -3.26 | -12.21% |
| S2 | 24.71 | -1.96 | -7.34% |
| S3 | 25.36 | -1.31 | -4.92% |
| S4 | 26.01 | -0.66 | -2.46% |
BALAXI is trading Above CPR, indicating Bullishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ~
Trading Inside opening range
Balaxi Pharmaceuticals Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Balaxi Pharmaceuticals Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Balaxi Pharmaceuticals Ltd stood at 64.4% of traded volume, against a 20-day average of 71.3%.
Balaxi Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings Balaxi Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Balaxi Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 55 documents below.
Copy of Newspaper Publication
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Copy of Newspaper Publication.
Investor Presentation
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Investor Presentation
Updates
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding 'RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the…
Copy of Newspaper Publication
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Copy of Newspaper Publication
Updates
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding '''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the…
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Balaxi Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Balaxi Pharmaceuticals has declared, sequenced by announce and record date.
Balaxi Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Balaxi Pharmaceuticals Ltd: business, sector, key facts.
What Balaxi Pharmaceuticals Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Balaxi Pharmaceuticals Ltd operates in the Health Care Providers & Services industry under the Health Care sector, listed as NSE: BALAXI.
Balaxi Pharmaceuticals Limited is an international wholesale distributor of a diverse range of products, primarily focused on serving markets in Africa, the Caribbean Islands, and Latin America. The company's core business centers around the pharmaceutical sector, where it offers a broad selection of medications targeting various therapeutic areas. This includes crucial treatments for common ailments and infections such as antibiotics, analgesics (painkillers), and anti-malarial drugs, alongside other pharmaceutical products.
Beyond pharmaceuticals, Balaxi Pharmaceuticals Limited extends its distribution network to encompass fast-moving consumer goods (FMCG) and builders' hardware. In the FMCG realm, the company's offerings include essential items such as biscuits and toothpaste. The inclusion of these products demonstrates a strategy to diversify its portfolio and cater to a broader consumer base in the regions it serves. This multi-product approach likely allows the company to leverage its established distribution network for greater efficiency and market penetration.
Established in 1942 and headquartered in Hyderabad, India, Balaxi Pharmaceuticals Limited has a long history in international trade. The company operates as a subsidiary of Balaxi Overseas Private Limited, indicating a larger corporate structure with potentially broader resources and strategic direction. The name change from Balaxi Ventures Limited to Balaxi Pharmaceuticals Limited in October 2020 reflects a strategic focus on the pharmaceutical sector while maintaining its commitment to diversified product offerings within its established international markets.
In summary, Balaxi Pharmaceuticals Limited's business model is built upon a foundation of international wholesale distribution, skillfully navigating the complexities of supplying diverse product categories to various markets across Africa, the Caribbean, and Latin America. The company leverages its long-standing presence and established network to efficiently reach its target customer base, demonstrating a robust and adaptable business strategy in a dynamic international environment.
Questions investors ask about Balaxi Pharmaceuticals Ltd (BALAXI).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Balaxi Pharmaceuticals Ltd (BALAXI)?
The current share price of Balaxi Pharmaceuticals Ltd (BALAXI) is ₹26.67. Today, the stock has gained by ₹0.30 (1.14%), trading in a range of ₹26 to ₹27.3. The stock opened at ₹27 with a trading volume of 51,334 shares.
02Is Balaxi Pharmaceuticals Ltd stock a good investment for long-term?
Balaxi Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹126.65 crores, P/E ratio of 12.27, ROE of 3.75%, and ROCE of 13.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Balaxi Pharmaceuticals Ltd stock?
The 52-week high price of Balaxi Pharmaceuticals Ltd (BALAXI) is ₹55.64, while the 52-week low is ₹15.2. Currently trading at ₹26.67, the stock is 28.4% away from its 52-week low and 52.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Balaxi Pharmaceuticals Ltd stock at the current price?
Whether to buy Balaxi Pharmaceuticals Ltd stock at ₹26.67 depends on multiple factors. The stock is currently trading with a P/E ratio of 12.27 and P/B ratio of 0.48. Today's performance shows a gain of 1.14%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Balaxi Pharmaceuticals Ltd and when is the next dividend?
Balaxi Pharmaceuticals Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹26.67, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Balaxi Pharmaceuticals Ltd?
Balaxi Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 12.27, P/B Ratio: 0.48, ROE: 3.75%, ROCE: 13.00%, Dividend Yield: 0.00%, EPS: ₹1.72, Book Value: ₹41.98, and Debt-to-Equity: 0.23. The company's market cap stands at ₹126.65 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Balaxi Pharmaceuticals Ltd stock performing today in the market?
Balaxi Pharmaceuticals Ltd stock opened at ₹27 and is currently trading at ₹26.67, showing a gain of ₹0.30 (1.14%). The intraday high is ₹27.3 and low is ₹26. The trading volume stands at 51,334 shares, indicating moderate market participation today.
08What is the P/E ratio of Balaxi Pharmaceuticals Ltd and what does it indicate?
Balaxi Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 12.27, which means investors are willing to pay ₹12.27 for every ₹1 of earnings. With an EPS of ₹1.72, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Balaxi Pharmaceuticals Ltd (BALAXI) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B Blackbio DX (3BBLACKBIO) Share PricePeer
- Abbott India (ABBOTINDIA) Share PricePeer
- Acutaas Chemicals (ACUTAAS) Share PricePeer
- AHCL (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy